Search results
Showing 526 to 540 of 1257 results for pathway
Infliximab for treating moderate to severe plaque psoriasis (TA134)
Evidence-based recommendations on infliximab for treating moderate to severe psoriasis in adults.
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma (TA321)
Evidence-based recommendations on dabrafenib (Tafinlar) for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation.
This quality standard covers contraception for women, including emergency contraception. It describes high-quality care in priority areas for improvement.
View quality statements for QS129Show all sections
NICE has developed a medtech innovation briefing (MIB) on Cor-Knot for tying suture knots in valve surgery .
NICE has developed a medtech innovation briefing (MIB) on Accuro for guiding epidural or spinal anaesthesia .
MMprofiler for prognostic risk classification in multiple myeloma (MIB270)
NICE has developed a medtech innovation briefing (MIB) on MMprofiler for prognostic risk classification in multiple myeloma .
NPi-200 for pupillary light reflex in critical care patients (MIB235)
NICE has developed a medtech innovation briefing (MIB) on NPi-200 for pupillary light reflex in critical care patients .
Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis (TA708)
Evidence-based recommendations on budesonide as an orodispersible tablet for inducing remission of eosinophilic oesophagitis in adults.
Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments (TA881)
Evidence-based recommendations on ripretinib (Qinlock) for treating gastrointestinal stromal tumour in adults after 3 or more treatments.
Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA780)
Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated advanced renal cell carcinoma in adults.
Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments in adults.
Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA1077)
Evidence-based recommendations on nemolizumab (Nemluvio) for treating moderate to severe atopic dermatitis in people 12 years and over.
This guideline covers the diagnosis and management of diverticular disease in people aged 18 years and over. It aims to improve diagnosis and care and help people get timely information and advice, including advice about symptoms and when to seek help.
Evidence-based recommendations on Kurin Lock for blood culture collection.
NICE has developed a medtech innovation briefing (MIB) on The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs .